Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2016-11-21 Share Issue/Capital Cha…
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Appendix 3B - ESOP 14 pages 1.0MB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form submitted to the Australian Stock Exchange (ASX) by Admedus Ltd. It details the issuance of 200,000 unlisted options to employees under an Employee Share Option Plan, including terms such as exercise price and expiry date. The document includes detailed information about the securities issued, compliance with ASX listing rules, and calculation of placement capacity under ASX rules. This type of document is a formal announcement of a capital raising or share issue event, specifically the issue of new options and application for quotation of these securities on the ASX. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the appropriate classification is "Share Issue/Capital Change" (SHA). The document length and detail confirm it is the announcement itself, not just a brief notice or report publication announcement.
2016-11-21 English
CardioCel receives market approval in UAE 3 pages 466.1KB
Capital/Financing Update Classification · 70% confidence The document is an ASX announcement from Admedus Ltd dated November 21, 2016, regarding the market approval of their product CardioCel in the UAE and initial orders received. It is a corporate press release focused on product approval and market expansion, with no financial statements, regulatory certifications, or detailed financial data. The content is promotional and informational about business developments rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about product market approval and business expansion, which aligns best with the Capital/Financing Update (CAP) category as it relates to business growth and market activities, although not a direct financing event, it is the closest fit among the options provided. Confidence is moderate due to the announcement nature and lack of direct financing details, but it is not a report publication or regulatory filing.
2016-11-20 English
Chairman's Address to Shareholders 32 pages 6.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation containing strategic framework, business updates, financial highlights, market analysis, product information, clinical trial updates, and board member introductions. It includes forward-looking statements and operational details but does not contain formal financial statements or regulatory disclosures typical of annual or interim reports. The length (over 14,000 characters) and content suggest it is a comprehensive investor-focused presentation rather than a brief announcement or a formal report. There is no indication that this is a transcript of a call, a voting result, or a regulatory filing. The presence of strategic goals, market positioning, and operational updates aligns with the characteristics of an Investor Presentation (IP).
2016-11-09 English
Results of Annual General Meeting 2 pages 301.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'RESULTS OF 2016 ANNUAL GENERAL MEETING' and references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth). It provides the results of shareholder votes on resolutions at the AGM held on 10 November 2016. The content focuses on voting outcomes rather than the meeting materials or the full AGM report. The document length is short (1343 characters) and it explicitly states it is reporting the results of the AGM voting. Therefore, this fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2016-11-09 English
Appendix 3B - ESOP 14 pages 1.1MB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form submitted to the Australian Stock Exchange (ASX) announcing the issue of unlisted options to employees under an Employee Share Option Plan. It details the number of securities issued, their terms, and compliance with ASX listing rules, including placement capacity calculations under rules 7.1 and 7.1A. The document is a formal announcement of a capital raising event involving new securities issuance and application for quotation of these securities on the ASX. It does not contain financial statements, management discussion, or audit information, nor is it a report or transcript. Therefore, it fits the category of Capital/Financing Update (CAP).
2016-10-31 English
Appendix 4C - quarterly 7 pages 433.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C - Quarterly Report' and refers to financial results for the first quarter ending 30 September 2016. It contains detailed financial data including cash flow statements, operating highlights, and management commentary on quarterly performance and forecasts. The document is approximately 11,959 characters long, which is substantial and contains actual financial statements and analysis. The presence of quarterly financial data and commentary aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but a comprehensive quarterly financial report. Therefore, the appropriate classification is 'IR' for Interim / Quarterly Report. Q1 2017
2016-10-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.